BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17706593)

  • 21. Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase beta/zeta.
    Polytarchou C; Hatziapostolou M; Poimenidi E; Mikelis C; Papadopoulou A; Parthymou A; Papadimitriou E
    Int J Cancer; 2009 Apr; 124(8):1785-93. PubMed ID: 19058221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.
    Stylianou DC; Auf der Maur A; Kodack DP; Henke RT; Hohn S; Toretsky JA; Riegel AT; Wellstein A
    Oncogene; 2009 Sep; 28(37):3296-306. PubMed ID: 19633684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP β/ζ signaling by menin.
    Feng ZJ; Gao SB; Wu Y; Xu XF; Hua X; Jin GH
    Oncogene; 2010 Sep; 29(39):5416-26. PubMed ID: 20639902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knockdown of pleiotrophin increases the risk of preeclampsia following vitrified-thawed embryo transfer.
    Liu S; Wang F; Liu G
    Int J Oncol; 2018 Nov; 53(5):1847-1856. PubMed ID: 30226583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of pleiotrophin and its receptors in human placenta suggests roles in trophoblast life cycle and angiogenesis.
    Ball M; Carmody M; Wynne F; Dockery P; Aigner A; Cameron I; Higgins J; Smith SD; Aplin JD; Moore T
    Placenta; 2009 Jul; 30(7):649-53. PubMed ID: 19481257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor.
    Koutsioumpa M; Poimenidi E; Pantazaka E; Theodoropoulou C; Skoura A; Megalooikonomou V; Kieffer N; Courty J; Mizumoto S; Sugahara K; Papadimitriou E
    Mol Cancer; 2015 Feb; 14(1):19. PubMed ID: 25644401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking receptor protein tyrosine phosphatase beta/zeta: a potential therapeutic strategy for Parkinson's disease.
    Herradón G; Ezquerra L
    Curr Med Chem; 2009; 16(25):3322-9. PubMed ID: 19548869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo.
    Ulbricht U; Eckerich C; Fillbrandt R; Westphal M; Lamszus K
    J Neurochem; 2006 Sep; 98(5):1497-506. PubMed ID: 16923162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and localization of receptor protein tyrosine phosphatase β and its ligand pleiotrophin in the submandibular gland of mice.
    Adthapanyawanich K; Yamamoto M; Wakayama T; Nakata H; Keattikunpairoj S; Iseki S
    Arch Oral Biol; 2013 Feb; 58(2):181-91. PubMed ID: 23092607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Receptor Protein Tyrosine Phosphatase β/ζ Reduces Alcohol Intake in Rats.
    Calleja-Conde J; Fernández-Calle R; Zapico JM; Ramos A; de Pascual-Teresa B; Bühler KM; Echeverry-Alzate V; Giné E; Rodríguez de Fonseca F; López-Moreno JA; Herradón G
    Alcohol Clin Exp Res; 2020 May; 44(5):1037-1045. PubMed ID: 32154588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
    Li R; Morris SW
    Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
    Stoica GE; Kuo A; Powers C; Bowden ET; Sale EB; Riegel AT; Wellstein A
    J Biol Chem; 2002 Sep; 277(39):35990-8. PubMed ID: 12122009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A peptide corresponding to the C-terminal region of pleiotrophin inhibits angiogenesis in vivo and in vitro.
    Mikelis C; Lamprou M; Koutsioumpa M; Koutsioubas AG; Spyranti Z; Zompra AA; Spiliopoulos N; Vradis AA; Katsoris P; Spyroulias GA; Cordopatis P; Courty J; Papadimitriou E
    J Cell Biochem; 2011 Jun; 112(6):1532-43. PubMed ID: 21344482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin.
    Stoica GE; Kuo A; Aigner A; Sunitha I; Souttou B; Malerczyk C; Caughey DJ; Wen D; Karavanov A; Riegel AT; Wellstein A
    J Biol Chem; 2001 May; 276(20):16772-9. PubMed ID: 11278720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase.
    Bowden ET; Stoica GE; Wellstein A
    J Biol Chem; 2002 Sep; 277(39):35862-8. PubMed ID: 12107166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleiotrophin-induced endothelial cell migration is regulated by xanthine oxidase-mediated generation of reactive oxygen species.
    Tsirmoula S; Lamprou M; Hatziapostolou M; Kieffer N; Papadimitriou E
    Microvasc Res; 2015 Mar; 98():74-81. PubMed ID: 25582077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
    Webb TR; Slavish J; George RE; Look AT; Xue L; Jiang Q; Cui X; Rentrop WB; Morris SW
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):331-56. PubMed ID: 19275511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
    Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
    Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner.
    Poimenidi E; Theodoropoulou C; Koutsioumpa M; Skondra L; Droggiti E; van den Broek M; Koolwijk P; Papadimitriou E
    Vascul Pharmacol; 2016 May; 80():11-9. PubMed ID: 26924457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.